21.59 USD
+0.01 (+0.05%)
AVDL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While AVDL seems to be doing ok healthwise, there are quite some concerns on its profitability. AVDL is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year AVDL has reported negative net income.
In the past year AVDL had a positive cash flow from operations.
In the past 5 years AVDL reported 4 times negative net income.
In the past 5 years AVDL always reported negative operating cash flow.
1.2 Ratios
AVDL has a Return On Assets of -0.14%. This is in the better half of the industry: AVDL outperforms 77.08% of its industry peers.
AVDL has a better Return On Equity (-0.28%) than 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| ROIC | N/A |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 91.09%, AVDL belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
AVDL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AVDL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
2. Health
2.1 Basic Checks
AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVDL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AVDL has been increased compared to 5 years ago.
Compared to 1 year ago, AVDL has a worse debt to assets ratio.
2.2 Solvency
AVDL has an Altman-Z score of 7.87. This indicates that AVDL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.87, AVDL is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
The Debt to FCF ratio of AVDL is 1.80, which is an excellent value as it means it would take AVDL, only 1.80 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AVDL (1.80) is better than 94.79% of its industry peers.
AVDL has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.35, AVDL is in line with its industry, outperforming 40.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.8 | ||
| Altman-Z | 7.87 |
ROIC/WACCN/A
WACC7.76%
2.3 Liquidity
A Current Ratio of 2.76 indicates that AVDL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.76, AVDL is in line with its industry, outperforming 49.48% of the companies in the same industry.
AVDL has a Quick Ratio of 2.37. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.37, AVDL is in line with its industry, outperforming 49.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 100.00% over the past year.
Looking at the last year, AVDL shows a very strong growth in Revenue. The Revenue has grown by 79.88%.
Measured over the past years, AVDL shows a very strong growth in Revenue. The Revenue has been growing by 23.35% on average per year.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
3.2 Future
Based on estimates for the next years, AVDL will show a very strong growth in Earnings Per Share. The EPS will grow by 43.00% on average per year.
The Revenue is expected to grow by 25.12% on average over the next years. This is a very strong growth
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y43%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y25.12%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 26.17, the valuation of AVDL can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVDL indicates a somewhat cheap valuation: AVDL is cheaper than 73.44% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. AVDL is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.17 |
4.2 Price Multiples
75.52% of the companies in the same industry are more expensive than AVDL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 101.05 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVDL's earnings are expected to grow with 64.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.39%
EPS Next 3Y64.19%
5. Dividend
5.1 Amount
AVDL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:AVDL (12/26/2025, 8:00:00 PM)
21.59
+0.01 (+0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners90.53%
Inst Owner Change-11.9%
Ins Owners4.79%
Ins Owner Change1.1%
Market Cap1.96B
Revenue(TTM)248.52M
Net Income(TTM)-278.00K
Analysts70
Price Target21.48 (-0.51%)
Short Float %4.36%
Short Ratio1.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.03%
Min EPS beat(2)-100%
Max EPS beat(2)258.07%
EPS beat(4)2
Avg EPS beat(4)42.28%
Min EPS beat(4)-100%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)22.06%
EPS beat(12)4
Avg EPS beat(12)-2.88%
EPS beat(16)5
Avg EPS beat(16)-12.25%
Revenue beat(2)2
Avg Revenue beat(2)5.92%
Min Revenue beat(2)3.23%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)3.03%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.43%
PT rev (3m)4.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.73%
EPS NY rev (1m)-12.53%
EPS NY rev (3m)-13.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)0.77%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.17 | ||
| P/S | 7.87 | ||
| P/FCF | 101.05 | ||
| P/OCF | 56.61 | ||
| P/B | 19.91 | ||
| P/tB | 24.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.83
Fwd EY3.82%
FCF(TTM)0.21
FCFY0.99%
OCF(TTM)0.38
OCFY1.77%
SpS2.74
BVpS1.08
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.09% | ||
| FCFM | 7.79% |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.8 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.37 | ||
| Altman-Z | 7.87 |
F-Score4
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y43%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y25.12%
EBIT growth 1Y92.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year158.03%
EBIT Next 3Y69.86%
EBIT Next 5Y44.46%
FCF growth 1Y116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.82%
OCF growth 3YN/A
OCF growth 5YN/A
AVADEL PHARMACEUTICALS / AVDL FAQ
Can you provide the ChartMill fundamental rating for AVADEL PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 5 / 10 to AVDL.
Can you provide the valuation status for AVADEL PHARMACEUTICALS?
ChartMill assigns a valuation rating of 4 / 10 to AVADEL PHARMACEUTICALS (AVDL). This can be considered as Fairly Valued.
How profitable is AVADEL PHARMACEUTICALS (AVDL) stock?
AVADEL PHARMACEUTICALS (AVDL) has a profitability rating of 3 / 10.
What is the expected EPS growth for AVADEL PHARMACEUTICALS (AVDL) stock?
The Earnings per Share (EPS) of AVADEL PHARMACEUTICALS (AVDL) is expected to grow by 138.39% in the next year.